92 results on '"Fay WP"'
Search Results
2. Myocardial proinflammatory cytokine expression and left ventricular remodeling in patients with chronic mitral regurgitation.
- Author
-
Oral H, Sivasubramanian N, Dyke DB, Mehta RH, Grossman PM, Briesmiester K, Fay WP, Pagani FD, Bolling SF, Mann DL, Starling MR, Spinale FG, Oral, Hakan, Sivasubramanian, Natarajan, Dyke, David B, Mehta, Rajendra H, Grossman, P Michael, Briesmiester, Kerri, Fay, William P, and Pagani, Francis D
- Published
- 2003
3. PAI-1 Regulates the Cytoskeleton and Intrinsic Stiffness of Vascular Smooth Muscle Cells.
- Author
-
Khoukaz HB, Vadali M, Schoenherr A, Ramirez-Perez FI, Morales-Quinones M, Sun Z, Fujie S, Foote CA, Lyu Z, Zeng S, Augenreich MA, Cai D, Chen SY, Joshi T, Ji Y, Hill MA, Martinez-Lemus LA, and Fay WP
- Abstract
Background: Plasma concentration of PAI-1 (plasminogen activator inhibitor-1) correlates with arterial stiffness. Vascular smooth muscle cells (SMCs) express PAI-1, and the intrinsic stiffness of SMCs is a major determinant of total arterial stiffness. We hypothesized that PAI-1 promotes SMC stiffness by regulating the cytoskeleton and that pharmacological inhibition of PAI-1 decreases SMC and aortic stiffness., Methods: PAI-039, a specific inhibitor of PAI-1, and small interfering RNA were used to inhibit PAI-1 expression in cultured human SMCs. Effects of PAI-1 inhibition on SMC stiffness, F-actin (filamentous actin) content, and cytoskeleton-modulating enzymes were assessed. WT (wild-type) and PAI-1-deficient murine SMCs were used to determine PAI-039 specificity. RNA sequencing was performed to determine the effects of PAI-039 on SMC gene expression. In vivo effects of PAI-039 were assessed by aortic pulse wave velocity., Results: PAI-039 significantly reduced intrinsic stiffness of human SMCs, which was accompanied by a significant decrease in cytoplasmic F-actin content. PAI-1 gene knockdown also decreased cytoplasmic F-actin. PAI-1 inhibition significantly increased the activity of cofilin, an F-actin depolymerase, in WT murine SMCs, but not in PAI-1-deficient SMCs. RNA-sequencing analysis suggested that PAI-039 upregulates AMPK (AMP-activated protein kinase) signaling in SMCs, which was confirmed by Western blotting. Inhibition of AMPK prevented activation of cofilin by PAI-039. In mice, PAI-039 significantly decreased aortic stiffness and tunica media F-actin content without altering the elastin or collagen content., Conclusions: PAI-039 decreases intrinsic SMC stiffness and cytoplasmic stress fiber content. These effects are mediated by AMPK-dependent activation of cofilin. PAI-039 also decreases aortic stiffness in vivo. These findings suggest that PAI-1 is an important regulator of the SMC cytoskeleton and that pharmacological inhibition of PAI-1 has the potential to prevent and treat cardiovascular diseases involving arterial stiffening.
- Published
- 2024
- Full Text
- View/download PDF
4. Enhanced Reendothelialization and Thrombosis Prevention with a New Drug-Eluting Stent.
- Author
-
Cai D, Chen AC, Zhou R, Murashita T, Fay WP, and Chen SY
- Abstract
Purpose: The objective of the study is to test the efficacy of cyclopentenyl cytosine (CPEC)-coated stents on blocking artery stenosis, promoting reendothelialization, and reducing thrombosis., Methods: Scanning electron microscopy was employed to observe the morphological characteristics of stents coated with a mixture of CPEC and poly(lactic-co-glycolic acid) (PLGA) copolymer. PLGA has been used in various Food and Drug Administration (FDA)-approved therapeutic devices. In vitro release of CPEC was tested to measure the dynamic drug elution. Comparison between CPEC- and everolimus-coated stents on neointimal formation and thrombosis formation was conducted after being implanted into the human internal mammary artery and grafted to the mouse aorta., Results: Optimization in stent coating resulted in uniform and consistent coating with minimal variation. In vitro drug release tests demonstrated a gradual and progressive discharge of CPEC. CPEC- or everolimus-coated stents caused much less stenosis than bare-metal stents. However, CPEC stent-implanted arteries exhibited enhanced reendothelialization compared to everolimus stents. Mechanistically, CPEC-coated stents reduced the proliferation of vascular smooth muscle cells while simultaneously promoting reendothelialization. More significantly, unlike everolimus-coated stents, CPEC-coated stents showed a significant reduction in thrombosis formation even in the absence of ongoing anticoagulant treatment., Conclusions: The study establishes CPEC-coated stent as a promising new device for cardiovascular interventions. By enhancing reendothelialization and preventing thrombosis, CPEC offers advantages over conventional approaches, including the elimination of the need for anti-clogging drugs, which pave the way for improved therapeutic outcomes and management of atherosclerosis-related medical procedures., (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
5. In vitro biological responses of plasma nanocoatings for coronary stent applications.
- Author
-
Phan T, Jones JE, Chen M, Strawn TL, Khoukaz HB, Ji Y, Kumar A, Bowles DK, Fay WP, and Yu Q
- Subjects
- Animals, Swine, Stents, Blood Platelets metabolism, Blood Coagulation, Chromium Alloys, Endothelial Cells, Thrombosis prevention & control
- Abstract
In-stent restenosis and thrombosis remain to be long-term challenges in coronary stenting procedures. The objective of this study was to evaluate the in vitro biological responses of trimethylsilane (TMS) plasma nanocoatings modified with NH
3 /O2 (2:1 molar ratio) plasma post-treatment (TMS + NH3 /O2 nanocoatings) on cobalt chromium (CoCr) alloy L605 coupons, L605 stents, and 316L stainless steel (SS) stents. Surface properties of the plasma nanocoatings with up to 2-year aging time were characterized by wettability assessment and x-ray photoelectron spectroscopy (XPS). It was found that TMS + NH3 /O2 nanocoatings had a surface composition of 41.21 ± 1.06 at% oxygen, 31.90 ± 1.08 at% silicon, and 24.12 ± 1.7 at% carbon, and very small but essential amount of 2.77 ± 0.18 at% nitrogen. Surface chemical stability of the plasma coatings was noted with persistent O/Si atomic ratio of 1.292-1.413 and N/Si atomic ratio of ~0.087 through 2 years. The in vitro biological responses of plasma nanocoatings were studied by evaluating the cell proliferation and migration of porcine coronary artery endothelial cells (PCAECs) and smooth muscle cells (PCASMCs). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) assay results revealed that, after 7-day incubation, TMS + NH3 /O2 nanocoatings maintained a similar level of PCAEC proliferation while showing a decrease in the viability of PCASMCs by 73 ± 19% as compared with uncoated L605 surfaces. Cell co-culture of PCAECs and PCASMCs results showed that, the cell ratio of PCAEC/PCASMC on TMS + NH3 /O2 nanocoating surfaces was 1.5-fold higher than that on uncoated L605 surfaces, indicating enhanced selectivity for promoting PCAEC growth. Migration test showed comparable PCAEC migration distance for uncoated L605 and TMS + NH3 /O2 nanocoatings. In contrast, PCASMC migration distance was reduced nearly 8.5-fold on TMS + NH3 /O2 nanocoating surfaces as compared to the uncoated L605 surfaces. Platelet adhesion test using porcine whole blood showed lower adhered platelets distribution (by 70 ± 16%), reduced clotting attachment (by 54 ± 12%), and less platelet activation on TMS + NH3 /O2 nanocoating surfaces as compared with the uncoated L605 controls. It was further found that, under shear stress conditions of simulated blood flow, TMS + NH3 /O2 nanocoating significantly inhibited platelet adhesion compared to the uncoated 316L SS stents and TMS nanocoated 316L SS stents. These results indicate that TMS + NH3 /O2 nanocoatings are very promising in preventing both restenosis and thrombosis for coronary stent applications., (© 2023 Wiley Periodicals LLC.)- Published
- 2023
- Full Text
- View/download PDF
6. Do Fish Oil Supplements Reduce A-Fib?
- Author
-
Khoukaz HB, Vadali M, and Fay WP
- Subjects
- Humans, Fish Oils, Dietary Supplements, Cardiovascular Diseases, Fatty Acids, Omega-3
- Published
- 2022
7. A Biocompatibility Study of Plasma Nanocoatings onto Cobalt Chromium L605 Alloy for Cardiovascular Stent Applications.
- Author
-
Phan T, Jones JE, Chen M, Bowles DK, Fay WP, and Yu Q
- Abstract
The objective of this study was to evaluate the biocompatibility of trimethylsilane (TMS) plasma nanocoatings modified with NH
3 /O2 (2:1 molar ratio) plasma post-treatment onto cobalt chromium (CoCr) L605 alloy coupons and stents for cardiovascular stent applications. Biocompatibility of plasma nanocoatings was evaluated by coating adhesion, corrosion behavior, ion releasing, cytotoxicity, and cell proliferation. Surface chemistry and wettability were studied to understand effects of surface properties on biocompatibility. Results show that NH3 /O2 post-treated TMS plasma nanocoatings are hydrophilic with water contact angle of 48.5° and have a typical surface composition of O (39.39 at.%), Si (31.92 at.%), C (24.12 at.%), and N (2.77 at.%). The plasma nanocoatings were conformal to substrate surface topography and had excellent adhesion to the alloy substrates, as assessed by tape test (ASTM D3359), and showed no cracking or peeling off L605 stent surfaces after dilation. The plasma nanocoatings also improve the corrosion resistance of CoCr L605 alloy by increasing corrosion potential and decreasing corrosion rates with no pitting corrosion and no mineral adsorption layer. Ion releasing test revealed that Co, Cr, and Ni ion concentrations were reduced by 64-79%, 67-69%, and 57-72%, respectively, in the plasma-nanocoated L605 samples as compared to uncoated L605 control samples. The plasma nanocoatings showed no sign of cytotoxicity from the test results according to ISO 10993-05 and 10993-12. Seven-day cell culture demonstrated that, in comparison with the uncoated L605 control surfaces, the plasma nanocoating surfaces showed 62 ± 7.3% decrease in porcine coronary artery smooth muscle cells (PCASMCs) density and had comparable density of porcine coronary artery endothelial cells (PCAECs). These results suggest that TMS plasma nanocoatings with NH3 /O2 plasma post-treatment possess the desired biocompatibility for stent applications and support the hypothesis that nanocoated stents could be very effective for in-stent restenosis prevention.- Published
- 2022
- Full Text
- View/download PDF
8. CagA + Helicobacter pylori , Not CagA - Helicobacter pylori , Infection Impairs Endothelial Function Through Exosomes-Mediated ROS Formation.
- Author
-
Xia X, Zhang L, Wu H, Chen F, Liu X, Xu H, Cui Y, Zhu Q, Wang M, Hao H, Li DP, Fay WP, Martinez-Lemus LA, Hill MA, Xu C, and Liu Z
- Abstract
Background: Helicobacter pylori (H. pylori) infection increases the risk for atherosclerosis, and ROS are critical to endothelial dysfunction and atherosclerosis. CagA is a major H. pylori virulence factor associated with atherosclerosis. The present study aimed to test the hypothesis that CagA
+ H. pylori effectively colonizes gastric mucosa, and CagA+ H. pylori , but not CagA- H. pylori , infection impairs endothelial function through exosomes-mediated ROS formation., Methods: C57BL/6 were used to determine the colonization ability of CagA+ H. pylori and CagA- H. pylori . ROS production, endothelial function of thoracic aorta and atherosclerosis were measured in CagA+ H. pylori and CagA- H. pylori infected mice. Exosomes from CagA+ H. pylori and CagA- H. pylori or without H. pylori infected mouse serum or GES-1 were isolated and co-cultured with bEND.3 and HUVECs to determine how CagA+ H. pylori infection impairs endothelial function. Further, GW4869 was used to determine if CagA+ H. pylori infection could lead to endothelial dysfunction and atherosclerosis through an exosomes-mediated mechanism., Results: CagA+ H. pylori colonized gastric mucosa more effectively than CagA- H. pylori in mice. CagA+ H. pylori , not CagA- H. pylori , infection significantly increased aortic ROS production, decreased ACh-induced aortic relaxation, and enhanced early atherosclerosis formation, which were prevented with N-acetylcysteine treatment. Treatment with CagA-containing exosomes significantly increased intracellular ROS production in endothelial cells and impaired their function. Inhibition of exosomes secretion with GW4869 effectively prevented excessive aortic ROS production, endothelial dysfunction, and atherosclerosis in mice with CagA+ H. pylori infection., Conclusion: These data suggest that CagA+ H. pylori effectively colonizes gastric mucosa, impairs endothelial function, and enhances atherosclerosis via exosomes-mediated ROS formation in mice., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Xia, Zhang, Wu, Chen, Liu, Xu, Cui, Zhu, Wang, Hao, Li, Fay, Martinez-Lemus, Hill, Xu and Liu.)- Published
- 2022
- Full Text
- View/download PDF
9. Fish Oil Supplements for Prevention of Cardiovascular Disease: Response to Opponents.
- Author
-
Khoukaz HB, Golzy M, and Fay WP
- Subjects
- Dietary Supplements, Fish Oils therapeutic use, Humans, Cardiovascular Diseases epidemiology, Cardiovascular Diseases prevention & control, Fatty Acids, Omega-3 therapeutic use
- Published
- 2021
10. Janus Kinase 3 Deficiency Promotes Vascular Reendothelialization-Brief Report.
- Author
-
Wang YC, Cai D, Cui XB, Chuang YH, Fay WP, and Chen SY
- Subjects
- Animals, Cells, Cultured, Disease Models, Animal, Endothelial Cells pathology, Female, Hyperplasia, Janus Kinase 3 genetics, Male, Mice, Knockout, ApoE, Muscle, Smooth, Vascular enzymology, Muscle, Smooth, Vascular pathology, Rats, Sprague-Dawley, Signal Transduction, Vascular System Injuries genetics, Vascular System Injuries pathology, Mice, Rats, Endothelial Cells enzymology, Janus Kinase 3 deficiency, Re-Epithelialization, Vascular Remodeling, Vascular System Injuries enzymology
- Abstract
[Figure: see text].
- Published
- 2021
- Full Text
- View/download PDF
11. Fish Oil Supplements for Prevention of Cardiovascular Disease: The Jury Is Still Out: CON: Fish Oil is Useful to Prevent or Treat Cardiovascular Disease.
- Author
-
Khoukaz HB and Fay WP
- Subjects
- Dietary Supplements, Docosahexaenoic Acids therapeutic use, Fish Oils therapeutic use, Humans, Cardiovascular Diseases epidemiology, Cardiovascular Diseases prevention & control, Fatty Acids, Omega-3 therapeutic use
- Abstract
Consumption of oily fish high in omega-3 fatty acids (n-3FAs) is strongly associated with reduced risk of adverse cardiovascular events. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are the n-3FAs in fish oil believed to confer its beneficial effects. Over the past two decades, multiple clinical trials have been conducted to test the hypothesis that encapsulated EPA and DHA supplements improve cardiovascular outcomes in patients with established cardiovascular disease or at risk of developing it. Over the same time period, over-the-counter fish oil supplements have become a multi-billion-dollar industry. In this article, we briefly review available clinical trial data involving EPA and DHA supplementation. Based on currently available information, we conclude that combination capsules containing EPA and DHA should not be used to reduce cardiovascular risk. Some studies suggest that EPA as stand-alone therapy decreases cardiovascular risk. Nevertheless, we advocate a restrictive approach to using EPA to improve cardiovascular outcomes., (Copyright 2021 by the Missouri State Medical Association.)
- Published
- 2021
12. Elevated postischemic tissue injury and leukocyte-endothelial adhesive interactions in mice with global deficiency in caveolin-2: role of PAI-1.
- Author
-
Liu Y, Wang M, Wang D, Fay WP, Korthuis RJ, and Sowa G
- Subjects
- Animals, Caveolin 2 genetics, Disease Models, Animal, Endothelial Cells pathology, Jejunal Diseases genetics, Jejunal Diseases pathology, Leukocytes pathology, Male, Mice, Inbred C57BL, Mice, Knockout, Reperfusion Injury genetics, Reperfusion Injury pathology, Signal Transduction, Venules pathology, Mice, Caveolin 2 deficiency, Cell Adhesion, Endothelial Cells metabolism, Jejunal Diseases metabolism, Jejunum blood supply, Leukocyte Rolling, Leukocytes metabolism, Plasminogen Activator Inhibitor 1 metabolism, Reperfusion Injury metabolism, Transendothelial and Transepithelial Migration, Venules metabolism
- Abstract
Ischemia/reperfusion (I/R)-induced rapid inflammation involving activation of leukocyte-endothelial adhesive interactions and leukocyte infiltration into tissues is a major contributor to postischemic tissue injury. However, the molecular mediators involved in this pathological process are not fully known. We have previously reported that caveolin-2 (Cav-2), a protein component of plasma membrane caveolae, regulated leukocyte infiltration in mouse lung carcinoma tumors. The goal of the current study was to examine if Cav-2 plays a role in I/R injury and associated acute leukocyte-mediated inflammation. Using a mouse small intestinal I/R model, we demonstrated that I/R downregulates Cav-2 protein levels in the small bowel. Further study using Cav-2-deficient mice revealed aggravated postischemic tissue injury determined by scoring of villi length in H&E-stained tissue sections, which correlated with increased numbers of MPO-positive tissue-infiltrating leukocytes determined by IHC staining. Intravital microscopic analysis of upstream events relative to leukocyte transmigration and tissue infiltration revealed that leukocyte-endothelial cell adhesive interactions in postcapillary venules, namely leukocyte rolling and adhesion were also enhanced in Cav-2-deficient mice. Mechanistically, Cav-2 deficiency increased plasminogen activator inhibitor-1 (PAI-1) protein levels in the intestinal tissue and a pharmacological inhibition of PAI-1 had overall greater inhibitory effect on both aggravated I/R tissue injury and enhanced leukocyte-endothelial interactions in postcapillary venules in Cav-2-deficient mice. In conclusion, our data suggest that Cav-2 protein alleviates tissue injury in response to I/R by dampening PAI-1 protein levels and thereby reducing leukocyte-endothelial adhesive interactions. NEW & NOTEWORTHY The role of caveolin-2 in regulating ischemia/reperfusion (I/R) tissue injury and the mechanisms underlying its effects are unknown. This study uses caveolin-2-deficient mouse and small intestinal I/R injury models to examine the role of caveolin-2 in the leukocyte-dependent reperfusion injury. We demonstrate for the first time that caveolin-2 plays a protective role from the I/R-induced leukocyte-dependent reperfusion injury by reducing PAI-1 protein levels in intestinal tissue and leukocyte-endothelial adhesive interactions in postcapillary venules.
- Published
- 2021
- Full Text
- View/download PDF
13. Drug Targeting of Plasminogen Activator Inhibitor-1 Inhibits Metabolic Dysfunction and Atherosclerosis in a Murine Model of Metabolic Syndrome.
- Author
-
Khoukaz HB, Ji Y, Braet DJ, Vadali M, Abdelhamid AA, Emal CD, Lawrence DA, and Fay WP
- Subjects
- Animals, Cellular Senescence drug effects, Diet, Western, Disease Models, Animal, Indoleacetic Acids administration & dosage, Macrophages drug effects, Macrophages pathology, Metabolic Syndrome pathology, Metabolic Syndrome prevention & control, Mice, Mice, Knockout, Obesity etiology, Obesity prevention & control, Plaque, Atherosclerotic pathology, Plasminogen Activator Inhibitor 1 physiology, Receptors, LDL deficiency, Receptors, LDL genetics, Atherosclerosis prevention & control, Metabolic Syndrome drug therapy, Plasminogen Activator Inhibitor 1 drug effects
- Abstract
Objective: Enhanced expression of PAI-1 (plasminogen activator inhibitor-1) has been implicated in atherosclerosis formation in humans with obesity and metabolic syndrome. However, little is known about the effects of pharmacological targeting of PAI-1 on atherogenesis. This study examined the effects of pharmacological PAI-1 inhibition on atherosclerosis formation in a murine model of obesity and metabolic syndrome. Approach and Results: LDL receptor-deficient ( ldlr
-/- ) mice were fed a Western diet high in cholesterol, fat, and sucrose to induce obesity, metabolic dysfunction, and atherosclerosis. Western diet triggered significant upregulation of PAI-1 expression compared with normal diet controls. Addition of a pharmacological PAI-1 inhibitor (either PAI-039 or MDI-2268) to Western diet significantly inhibited obesity and atherosclerosis formation for up to 24 weeks without attenuating food consumption. Pharmacological PAI-1 inhibition significantly decreased macrophage accumulation and cell senescence in atherosclerotic plaques. Recombinant PAI-1 stimulated smooth muscle cell senescence, whereas a PAI-1 mutant defective in LRP1 (LDL receptor-related protein 1) binding did not. The prosenescent effect of PAI-1 was blocked by PAI-039 and R2629, a specific anti-LRP1 antibody. PAI-039 significantly decreased visceral adipose tissue inflammation, hyperglycemia, and hepatic triglyceride content without altering plasma lipid profiles., Conclusions: Pharmacological targeting of PAI-1 inhibits atherosclerosis in mice with obesity and metabolic syndrome, while inhibiting macrophage accumulation and cell senescence in atherosclerotic plaques, as well as obesity-associated metabolic dysfunction. PAI-1 induces senescence of smooth muscle cells in an LRP1-dependent manner. These results help to define the role of PAI-1 in atherosclerosis formation and suggest a new plasma-lipid-independent strategy for inhibiting atherogenesis.- Published
- 2020
- Full Text
- View/download PDF
14. Overproduction of endothelin-1 impairs glucose tolerance but does not promote visceral adipose tissue inflammation or limit metabolic adaptations to exercise.
- Author
-
Jurrissen TJ, Grunewald ZI, Woodford ML, Winn NC, Ball JR, Smith TN, Wheeler AA, Rawlings AL, Staveley-O'Carroll KF, Ji Y, Fay WP, Paradis P, Schiffrin EL, Vieira-Potter VJ, Fadel PJ, Martinez-Lemus LA, and Padilla J
- Subjects
- Animals, Body Mass Index, Endothelin-1 antagonists & inhibitors, Endothelin-1 genetics, Exercise physiology, Female, Gene Expression, Humans, Mice, Mice, Inbred C57BL, Mice, Knockout, Mice, Obese, Obesity pathology, Running, Endothelin-1 metabolism, Glucose Intolerance metabolism, Inflammation pathology, Intra-Abdominal Fat pathology, Physical Conditioning, Animal physiology
- Abstract
Endothelin-1 (ET-1) is a potent vasoconstrictor and proinflammatory peptide that is upregulated in obesity. Herein, we tested the hypothesis that ET-1 signaling promotes visceral adipose tissue (AT) inflammation and disrupts glucose homeostasis. We also tested if reduced ET-1 is a required mechanism by which exercise ameliorates AT inflammation and improves glycemic control in obesity. We found that 1 ) diet-induced obesity, AT inflammation, and glycemic dysregulation were not accompanied by significantly increased levels of ET-1 in AT or circulation in wild-type mice and that endothelial overexpression of ET-1 and consequently increased ET-1 levels did not cause AT inflammation yet impaired glucose tolerance; 2 ) reduced AT inflammation and improved glucose tolerance with voluntary wheel running was not associated with decreased levels of ET-1 in AT or circulation in obese mice nor did endothelial overexpression of ET-1 impede such exercise-induced metabolic adaptations; 3 ) chronic pharmacological blockade of ET-1 receptors did not suppress AT inflammation in obese mice but improved glucose tolerance; and 4 ) in a cohort of human subjects with a wide range of body mass indexes, ET-1 levels in AT, or circulation were not correlated with markers of inflammation in AT. In aggregate, we conclude that ET-1 signaling is not implicated in the development of visceral AT inflammation but promotes glucose intolerance, thus representing an important therapeutic target for glycemic dysregulation in conditions characterized by hyperendothelinemia. Furthermore, we show that the salutary effects of exercise on AT and systemic metabolic function are not contingent on the suppression of ET-1 signaling.
- Published
- 2019
- Full Text
- View/download PDF
15. The association of Klippel-Trenaunay syndrome and abdominal aortic aneurysms.
- Author
-
Braet DJ, Khoukaz HB, Vogel TR, Tewari SO, and Fay WP
- Published
- 2019
- Full Text
- View/download PDF
16. No Sweetie Pie: Newly Uncovered Role for PAI (Plasminogen Activator Inhibitor)-1 in Inflammatory Responses to Ischemia/Reperfusion.
- Author
-
Fay WP and Korthuis RJ
- Subjects
- Humans, Ischemia, Reperfusion, Neutrophil Infiltration, Plasminogen Activator Inhibitor 1
- Published
- 2018
- Full Text
- View/download PDF
17. Plasminogen activator inhibitor-1 regulates the vascular expression of vitronectin.
- Author
-
Luo M, Ji Y, Luo Y, Li R, Fay WP, and Wu J
- Subjects
- Animals, Cells, Cultured, Gene Expression Regulation, Humans, Low Density Lipoprotein Receptor-Related Protein-1, Mice, Mice, Inbred C57BL, Mice, Knockout, Mice, Transgenic, Muscle, Smooth, Vascular cytology, Myocytes, Smooth Muscle cytology, Myocytes, Smooth Muscle metabolism, Neointima etiology, Neointima genetics, Neointima metabolism, RNA, Small Interfering genetics, Receptors, LDL metabolism, Recombinant Proteins genetics, Recombinant Proteins metabolism, Serpin E2 deficiency, Serpin E2 genetics, Tumor Suppressor Proteins metabolism, Vascular Remodeling, Vitronectin deficiency, Vitronectin genetics, Muscle, Smooth, Vascular metabolism, Serpin E2 metabolism, Vitronectin metabolism
- Abstract
Essentials Vitronectin (VN) is produced by smooth muscle cells (SMCs) and promotes neointima formation. We studied the regulation of vascular VN expression by plasminogen activator inhibitor-1 (PAI-1). PAI-1 stimulates VN gene expression in SMCs by binding LDL receptor-related protein 1. Stimulation of VN gene expression may be a mechanism by which PAI-1 controls vascular remodeling., Summary: Background Increased expression of vitronectin (VN) by smooth muscle cells (SMCs) promotes neointima formation after vascular injury, and may contribute to chronic vascular diseases, such as atherosclerosis. However, the molecular regulation of vascular VN expression is poorly defined. Given the overlapping expression profiles and functions of VN and plasminogen activator inhibitor (PAI)-1, we hypothesized that PAI-1 regulates vascular VN expression. Objectives To determine whether PAI-1 regulates VN expression in SMCs and in vivo. Methods The effects of genetic alterations in PAI-1 expression, pharmacologic PAI-1 inhibition and recombinant PAI-1 on SMC VN expression were studied, and vascular VN expression in wild-type (WT) and PAI-1-deficient mice was assessed. Results VN expression was significantly lower in PAI-1-deficient SMCs and significantly increased in PAI-1-overexpressing SMCs. PAI-1 small interfering RNA and pharmacologic PAI-1 inhibition significantly decreased SMC VN expression. Recombinant PAI-1 stimulated VN expression by binding LDL receptor-related protein-1 (LRP1), but another LRP1 ligand, α
2 -macroglobulin, did not. As compared with WT controls, carotid artery VN expression was significantly lower in PAI-1-deficient mice and significantly higher in PAI-1-transgenic mice. In a vein graft (VG) model of intimal hyperplasia, VN expression was significantly attenuated in PAI-1-deficient VGs as compared with WT controls. The plasma VN concentration was significantly decreased in PAI-1-deficient mice versus WT controls at 4 weeks, but not at 5 days or 8 weeks, after surgery. Conclusions PAI-1 stimulates SMC VN expression by binding LRP1, and controls vascular VN expression in vivo. Autocrine regulation of vascular VN expression by PAI-1 may play important roles in vascular homeostasis and pathologic vascular remodeling., (© 2017 International Society on Thrombosis and Haemostasis.)- Published
- 2017
- Full Text
- View/download PDF
18. Recombinant soluble apyrase APT102 inhibits thrombosis and intimal hyperplasia in vein grafts without adversely affecting hemostasis or re-endothelialization.
- Author
-
Ji Y, Adeola O, Strawn TL, Jeong SS, Chen R, and Fay WP
- Subjects
- Adenosine chemistry, Adenosine Triphosphatases chemistry, Animals, Blood Platelets cytology, Carotid Arteries pathology, Cell Movement, Cell Proliferation, Coronary Vessels pathology, Endothelial Cells pathology, Endothelium, Vascular pathology, Hemostasis, Humans, Hyperplasia, Male, Mice, Mice, Inbred C57BL, Muscle, Smooth, Vascular pathology, Myocytes, Smooth Muscle cytology, Platelet Aggregation, Prothrombin Time, Solubility, Tunica Intima pathology, Apyrase pharmacology, Blood Vessels transplantation, Recombinant Proteins pharmacology, Thrombosis drug therapy, Tunica Intima drug effects
- Abstract
Essentials New strategies are needed to inhibit thrombosis and intimal hyperplasia (IH) in vein grafts (VG). We studied effects of apyrase (APT102) on VGs and smooth muscle and endothelial cells (SMC/EC). APT102 inhibited thrombosis, SMC migration, and IH without impairing hemostasis or EC recovery. Apyrase APT102 is a single-drug approach to inhibit multiple processes that cause VG failure., Summary: Background Occlusion of vein grafts (VGs) after bypass surgery, owing to thrombosis and intimal hyperplasia (IH), is a major clinical problem. Apyrases are enzymes that scavenge extracellular ATP and ADP, and promote adenosine formation at sites of vascular injury, and hence have the potential to inhibit VG pathology. Objectives To examine the effects of recombinant soluble human apyrase, APT102, on platelets, smooth muscle cells (SMCs) and endothelial cells (ECs) in vitro, and on thrombosis and IH in murine VGs. Methods SMC and EC proliferation and migration were studied in vitro. Inferior vena cava segments from donor mice were grafted into carotid arteries of recipient mice. Results APT102 potently inhibited ADP-induced platelet aggregation and VG thrombosis, but it did not impair surgical hemostasis. APT102 did not directly inhibit SMC or EC proliferation, but significantly attenuated the effects of ATP on SMC and EC proliferation. APT102 significantly inhibited SMC migration, but did not inhibit EC migration, which may be mediated, at least in part, by inhibition of SMC, but not EC, migration by adenosine. At 4 weeks after surgery, there was significantly less IH in VGs of APT102-treated mice than in control VGs. APT102 significantly inhibited cell proliferation in VGs, but did not inhibit re-endothelialization. Conclusions Systemic administration of a recombinant human apyrase inhibits thrombosis and IH in VGs without increasing bleeding or compromising re-endothelialization. These results suggest that APT102 has the potential to become a novel, single-drug treatment strategy to prevent multiple pathologic processes that drive early adverse remodeling and occlusion of VGs., (© 2017 International Society on Thrombosis and Haemostasis.)
- Published
- 2017
- Full Text
- View/download PDF
19. Targeting TRAF3IP2 by Genetic and Interventional Approaches Inhibits Ischemia/Reperfusion-induced Myocardial Injury and Adverse Remodeling.
- Author
-
Erikson JM, Valente AJ, Mummidi S, Kandikattu HK, DeMarco VG, Bender SB, Fay WP, Siebenlist U, and Chandrasekar B
- Subjects
- Adaptor Proteins, Signal Transducing genetics, Animals, Gene Deletion, Mice, Mice, Knockout, Myocytes, Cardiac metabolism, Oxidative Stress, Reactive Nitrogen Species metabolism, Adaptor Proteins, Signal Transducing metabolism, Myocardial Reperfusion Injury prevention & control, Ventricular Remodeling
- Abstract
Re-establishing blood supply is the primary goal for reducing myocardial injury in subjects with ischemic heart disease. Paradoxically, reperfusion results in nitroxidative stress and a marked inflammatory response in the heart. TRAF3IP2 (TRAF3 Interacting Protein 2; previously known as CIKS or Act1) is an oxidative stress-responsive cytoplasmic adapter molecule that is an upstream regulator of both IκB kinase (IKK) and c-Jun N-terminal kinase (JNK), and an important mediator of autoimmune and inflammatory responses. Here we investigated the role of TRAF3IP2 in ischemia/reperfusion (I/R)-induced nitroxidative stress, inflammation, myocardial dysfunction, injury, and adverse remodeling. Our data show that I/R up-regulates TRAF3IP2 expression in the heart, and its gene deletion, in a conditional cardiomyocyte-specific manner, significantly attenuates I/R-induced nitroxidative stress, IKK/NF-κB and JNK/AP-1 activation, inflammatory cytokine, chemokine, and adhesion molecule expression, immune cell infiltration, myocardial injury, and contractile dysfunction. Furthermore, Traf3ip2 gene deletion blunts adverse remodeling 12 weeks post-I/R, as evidenced by reduced hypertrophy, fibrosis, and contractile dysfunction. Supporting the genetic approach, an interventional approach using ultrasound-targeted microbubble destruction-mediated delivery of phosphorothioated TRAF3IP2 antisense oligonucleotides into the LV in a clinically relevant time frame significantly inhibits TRAF3IP2 expression and myocardial injury in wild type mice post-I/R. Furthermore, ameliorating myocardial damage by targeting TRAF3IP2 appears to be more effective to inhibiting its downstream signaling intermediates NF-κB and JNK. Therefore, TRAF3IP2 could be a potential therapeutic target in ischemic heart disease., (© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.)
- Published
- 2017
- Full Text
- View/download PDF
20. Pharmacological Targeting of Plasminogen Activator Inhibitor-1 Decreases Vascular Smooth Muscle Cell Migration and Neointima Formation.
- Author
-
Ji Y, Weng Z, Fish P, Goyal N, Luo M, Myears SP, Strawn TL, Chandrasekar B, Wu J, and Fay WP
- Subjects
- Animals, Carotid Artery Injuries genetics, Carotid Artery Injuries metabolism, Carotid Artery Injuries pathology, Cells, Cultured, Disease Models, Animal, Dose-Response Relationship, Drug, Endothelial Cells drug effects, Endothelial Cells metabolism, Endothelial Cells pathology, Genotype, Humans, Hyperplasia, Janus Kinases metabolism, Low Density Lipoprotein Receptor-Related Protein-1, Male, Mice, Inbred C57BL, Mice, Knockout, Molecular Targeted Therapy, Muscle, Smooth metabolism, Muscle, Smooth pathology, Muscle, Smooth transplantation, Muscle, Smooth, Vascular metabolism, Muscle, Smooth, Vascular pathology, Muscle, Smooth, Vascular transplantation, Phenotype, Phosphorylation, Plasminogen Activator Inhibitor 1 deficiency, Plasminogen Activator Inhibitor 1 genetics, Re-Epithelialization drug effects, Receptors, LDL deficiency, Receptors, LDL genetics, STAT1 Transcription Factor metabolism, Signal Transduction drug effects, Tumor Suppressor Proteins deficiency, Tumor Suppressor Proteins genetics, Vascular Remodeling drug effects, Vena Cava, Inferior drug effects, Vena Cava, Inferior metabolism, Vena Cava, Inferior pathology, Vena Cava, Inferior transplantation, Carotid Artery Injuries drug therapy, Cell Movement drug effects, Cell Proliferation drug effects, Indoleacetic Acids pharmacology, Muscle, Smooth drug effects, Muscle, Smooth, Vascular drug effects, Neointima, Plasminogen Activator Inhibitor 1 metabolism, Serine Proteinase Inhibitors pharmacology
- Abstract
Objective: Plasminogen activator inhibitor-1 (PAI-1), a serine protease inhibitor that promotes and inhibits cell migration, plays a complex and important role in adverse vascular remodeling. Little is known about the effects of pharmacological PAI-1 inhibitors, an emerging drug class, on migration of vascular smooth muscle cells (SMCs) and endothelial cells (ECs), crucial mediators of vascular remodeling. We investigated the effects of PAI-039 (tiplaxtinin), a specific PAI-1 inhibitor, on SMC and EC migration in vitro and vascular remodeling in vivo., Approach and Results: PAI-039 inhibited SMC migration through collagen gels, including those supplemented with vitronectin and other extracellular matrix proteins, but did not inhibit migration of PAI-1-deficient SMCs, suggesting that its antimigratory effects were PAI-1-specific and physiologically relevant. However, PAI-039 did not inhibit EC migration. PAI-039 inhibited phosphorylation and nuclear translocation of signal transducers and activators of transcription-1 in SMCs, but had no discernable effect on signal transducer and activator of transcription-1 signaling in ECs. Expression of low-density lipoprotein receptor-related protein 1, a motogenic PAI-1 receptor that activates Janus kinase/signal transducers and activators of transcription-1 signaling, was markedly lower in ECs than in SMCs. Notably, PAI-039 significantly inhibited intimal hyperplasia and inflammation in murine models of adverse vascular remodeling, but did not adversely affect re-endothelialization after endothelium-denuding mechanical vascular injury., Conclusions: PAI-039 inhibits SMC migration and intimal hyperplasia, while having no inhibitory effect on ECs, which seems to be because of differences in PAI-1-dependent low-density lipoprotein receptor-related protein 1/Janus kinase/signal transducer and activator of transcription-1 signaling between SMCs and ECs. These findings suggest that PAI-1 may be an important therapeutic target in obstructive vascular diseases characterized by neointimal hyperplasia., Competing Interests: The authors have no financial or other conflicts of interests., (© 2016 American Heart Association, Inc.)
- Published
- 2016
- Full Text
- View/download PDF
21. The Nox1/4 Dual Inhibitor GKT137831 or Nox4 Knockdown Inhibits Angiotensin-II-Induced Adult Mouse Cardiac Fibroblast Proliferation and Migration. AT1 Physically Associates With Nox4.
- Author
-
Somanna NK, Valente AJ, Krenz M, Fay WP, Delafontaine P, and Chandrasekar B
- Subjects
- Aging, Animals, Cell Proliferation drug effects, Enzyme Activation drug effects, Humans, Interleukin-18 metabolism, Male, Matrix Metalloproteinase 9 metabolism, Mice, Inbred C57BL, NADPH Oxidase 4, NF-kappa B metabolism, Oxidative Stress drug effects, Protein Binding drug effects, Pyrazolones, Pyridones, Reactive Oxygen Species metabolism, Transcription Factor AP-1 metabolism, Angiotensin II pharmacology, Cell Movement drug effects, Fibroblasts cytology, Gene Knockdown Techniques, Myocardium cytology, NADPH Oxidases metabolism, Pyrazoles pharmacology, Pyridines pharmacology, Receptor, Angiotensin, Type 1 metabolism
- Abstract
Both oxidative stress and inflammation contribute to chronic hypertension-induced myocardial fibrosis and adverse cardiac remodeling. Here we investigated whether angiotensin (Ang)-II-induced fibroblast proliferation and migration are NADPH oxidase (Nox) 4/ROS and IL-18 dependent. Our results show that the potent induction of mouse cardiac fibroblast (CF) proliferation and migration by Ang-II is markedly attenuated by Nox4 knockdown and the Nox inhibitor DPI. Further, Nox4 knockdown and DPI pre-treatment attenuated Ang-II-induced IL-18, IL-18Rα and collagen expression, and MMP9 and LOX activation. While neutralization of IL-18 blunted Ang-II-induced CF proliferation and migration, knockdown of MMP9 attenuated CF migration. The antioxidant NAC and the cell-permeable SOD mimetics Tempol, MnTBAP, and MnTMPyP attenuated oxidative stress and inhibited CF proliferation and migration. The Nox1/Nox4 dual inhibitor GKT137831 also blunted Ang-II-induced H2 O2 production and CF proliferation and migration. Further, AT1 bound Nox4, and Ang-II enhanced their physical association. Notably, GKT137831 attenuated the AT1/Nox4 interaction. These results indicate that Ang-II induces CF proliferation and migration in part via Nox4/ROS-dependent IL-18 induction and MMP9 activation, and may involve AT1/Nox4 physical association. Thus, either (i) neutralizing IL-18, (ii) blocking AT1/Nox4 interaction or (iii) use of the Nox1/Nox4 inhibitor GKT137831 may have therapeutic potential in chronic hypertension-induced adverse cardiac remodeling., Competing Interests: None., (© 2015 Wiley Periodicals, Inc.)
- Published
- 2016
- Full Text
- View/download PDF
22. Laminin Receptor-Avid Nanotherapeutic EGCg-AuNPs as a Potential Alternative Therapeutic Approach to Prevent Restenosis.
- Author
-
Khoobchandani M, Katti K, Maxwell A, Fay WP, and Katti KV
- Subjects
- Anti-Inflammatory Agents administration & dosage, Anti-Inflammatory Agents pharmacokinetics, Anti-Inflammatory Agents pharmacology, Antioxidants pharmacokinetics, Catechin administration & dosage, Catechin pharmacokinetics, Catechin pharmacology, Cell Line, Cell Movement drug effects, Cell Proliferation drug effects, Coronary Restenosis prevention & control, Endothelial Cells cytology, Endothelial Cells drug effects, Endothelial Cells metabolism, Human Umbilical Vein Endothelial Cells, Humans, Myocytes, Smooth Muscle cytology, Myocytes, Smooth Muscle drug effects, Myocytes, Smooth Muscle metabolism, Receptors, Laminin metabolism, Ribosomal Proteins, Antioxidants administration & dosage, Antioxidants pharmacology, Catechin analogs & derivatives, Drug Carriers chemistry, Gold chemistry, Metal Nanoparticles chemistry
- Abstract
In our efforts to develop new approaches to treat and prevent human vascular diseases, we report herein our results on the proliferation and migration of human smooth muscles cells (SMCs) and endothelial cells (ECs) using epigallocatechin-3-gallate conjugated gold nanoparticles (EGCg-AuNPs) as possible alternatives to drug coated stents. Detailed in vitro stability studies of EGCg-AuNPs in various biological fluids, affinity and selectivity towards SMCs and ECs have been investigated. The EGCg-AuNPs showed selective inhibitory efficacy toward the migration of SMCs. However, the endothelial cells remained unaffected under similar experimental conditions. The cellular internalization studies have indicated that EGCg-AuNPs internalize into the SMCs and ECs within short periods of time through laminin receptor mediated endocytosis mode. Favorable toxicity profiles and selective affinity toward SMCs and ECs suggest that EGCg-AuNPs may provide attractive alternatives to drug coated stents and therefore offer new therapeutic approaches in treating cardiovascular diseases.
- Published
- 2016
- Full Text
- View/download PDF
23. Bevacizumab promotes venous thromboembolism through the induction of PAI-1 in a mouse xenograft model of human lung carcinoma.
- Author
-
Chen N, Ren M, Li R, Deng X, Li Y, Yan K, Xiao L, Yang Y, Wang L, Luo M, Fay WP, and Wu J
- Subjects
- Adenocarcinoma complications, Adenocarcinoma drug therapy, Adenocarcinoma of Lung, Animals, Bevacizumab administration & dosage, Carcinoma, Non-Small-Cell Lung complications, Carcinoma, Non-Small-Cell Lung drug therapy, Cell Line, Tumor, Disease Models, Animal, Gene Expression Regulation, Neoplastic drug effects, Humans, Lung Neoplasms complications, Lung Neoplasms drug therapy, Mice, Plasminogen Activator Inhibitor 1 genetics, Vascular Endothelial Growth Factor A antagonists & inhibitors, Venous Thromboembolism chemically induced, Venous Thromboembolism etiology, Xenograft Model Antitumor Assays, Adenocarcinoma pathology, Bevacizumab adverse effects, Carcinoma, Non-Small-Cell Lung pathology, Lung Neoplasms pathology, Plasminogen Activator Inhibitor 1 biosynthesis, Venous Thromboembolism pathology
- Abstract
Background: An increased incidence of venous thromboembolism (VTE) is associated with anti-vascular endothelial growth factor (VEGF) treatment in cancer. However, the mechanism underlying this effect remains elusive. In this study, we examined the effect of bevacizumab, a humanized monoclonal antibody against VEGF-A, on VTE in a murine xenograft A549 cell tumor model., Methods: Inferior vena cava stenosis model and FeCl3-induced saphenous vein thrombosis model were performed in a mouse xenograft models of human lung adenocarcinoma., Results: We found that treatment with bevacizumab significantly increased the thrombotic response to inferior vena cava obstruction and femoral vein injury. Plasminogen activator inhibitor (PAI-1) expression in tumors, plasma, and thrombi was significantly increased by bevacizumab. However, bevacizumab did not enhance VTE in PAI-1-deficient mice, suggesting that PAI-1 is a major mediator of bevacizumab's prothrombotic effect. VEGF inhibited expression of PAI-1 by A549 cells, and this effect was neutralized by bevacizumab, suggesting that bevacizumab increases PAI-1 expression in vivo by blocking the inhibitory effect of VEGF on PAI-1 expression by tumor cells. Pharmacological inhibition of PAI-1 with PAI-039 blocked bevacizumab-induced venous thrombosis., Conclusion: Collectively, these findings indicate that PAI-1 plays a role in VTE associated with antiangiogenic therapy and the inhibition of PAI-1 shows efficacy as a therapeutic strategy for the prevention of bevacizumab-associated VTE.
- Published
- 2015
- Full Text
- View/download PDF
24. Plasminogen activator inhibitor-1 inhibits angiogenic signaling by uncoupling vascular endothelial growth factor receptor-2-αVβ3 integrin cross talk.
- Author
-
Wu J, Strawn TL, Luo M, Wang L, Li R, Ren M, Xia J, Zhang Z, Ma W, Luo T, Lawrence DA, and Fay WP
- Subjects
- Animals, Cell Adhesion, Cell Movement, Cells, Cultured, Disease Models, Animal, Endocytosis, Endothelial Cells drug effects, Hindlimb, Human Umbilical Vein Endothelial Cells drug effects, Human Umbilical Vein Endothelial Cells metabolism, Humans, Indoleacetic Acids administration & dosage, Ischemia metabolism, Ischemia physiopathology, Ischemia prevention & control, Male, Mice, Inbred C57BL, Mice, Knockout, Mutation, Phosphorylation, Plasminogen Activator Inhibitor 1 genetics, RNA Interference, Receptors, LDL metabolism, Recombinant Proteins metabolism, Serine Proteinase Inhibitors administration & dosage, Time Factors, Transfection, Vitronectin deficiency, Vitronectin genetics, Endothelial Cells metabolism, Integrin alphaVbeta3 metabolism, Muscle, Skeletal blood supply, Neovascularization, Physiologic drug effects, Plasminogen Activator Inhibitor 1 metabolism, Receptor Cross-Talk drug effects, Signal Transduction drug effects, Vascular Endothelial Growth Factor Receptor-2 metabolism
- Abstract
Objective: Plasminogen activator inhibitor-1 (PAI-1) regulates angiogenesis via effects on extracellular matrix proteolysis and cell adhesion. However, no previous study has implicated PAI-1 in controlling vascular endothelial growth factor (VEGF) signaling. We tested the hypothesis that PAI-1 downregulates VEGF receptor-2 (VEGFR-2) activation by inhibiting a vitronectin-dependent cooperative binding interaction between VEGFR-2 and αVβ3., Approach and Results: We studied effects of PAI-1 on VEGF signaling in human umbilical vein endothelial cells. PAI-1 inhibited VEGF-induced phosphorylation of VEGFR-2 in human umbilical vein endothelial cells grown on vitronectin, but not on fibronectin or collagen. PAI-1 inhibited the binding of VEGFR-2 to β3 integrin, VEGFR-2 endocytosis, and intracellular signaling pathways downstream of VEGFR-2. The anti-VEGF effect of PAI-1 was mediated by 2 distinct pathways, one requiring binding to vitronectin and another requiring binding to very low-density lipoprotein receptor. PAI-1 inhibited VEGF-induced angiogenesis in vitro and in vivo, and pharmacological inhibition of PAI-1 promoted collateral arteriole development and recovery of hindlimb perfusion after femoral artery interruption., Conclusions: PAI-1 inhibits activation of VEGFR-2 by VEGF by disrupting a vitronectin-dependent proangiogenic binding interaction involving αVβ3 and VEGFR-2. These results broaden our understanding of the roles of PAI-1, vitronectin, and endocytic receptors in regulating VEGFR-2 activation and suggest novel therapeutic strategies for regulating VEGF signaling., (© 2014 American Heart Association, Inc.)
- Published
- 2015
- Full Text
- View/download PDF
25. C-reactive protein induces expression of tissue factor and plasminogen activator inhibitor-1 and promotes fibrin accumulation in vein grafts.
- Author
-
Ji Y, Fish PM, Strawn TL, Lohman AW, Wu J, Szalai AJ, and Fay WP
- Subjects
- Animals, Cell Movement, Chlorides chemistry, Coronary Artery Bypass, Ferric Compounds chemistry, Humans, Macrophages metabolism, Male, Mice, Mice, Inbred C57BL, Mice, Transgenic, Recombinant Proteins metabolism, Transgenes, Venous Thrombosis blood, C-Reactive Protein metabolism, Fibrin metabolism, Plasminogen Activator Inhibitor 1 metabolism, Thromboplastin metabolism, Veins transplantation
- Abstract
Background: C-reactive protein (CRP) promotes tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) expression in vitro, and an elevated plasma CRP concentration is associated with an increased risk of vein graft (VG) thrombosis after coronary artery bypass surgery. However, little is known about the effects of CRP on VG TF and PAI-1 expression in vivo, or on VG thrombosis., Objectives: We studied transgenic (Tg) mice expressing human CRP in a VG model to explore in vivo cause-and-effect relationships between CRP and TF, PAI-1, and VG thrombosis., Methods: Vein segments from wild-type (WT) and CRP-Tg donors were transplanted into carotid arteries of WT and CRP-Tg recipients. VGs were analyzed 1-4 weeks later., Results: Human CRP accumulated in VGs during the first 4 weeks after surgery, but appeared to originate exclusively from systemic sources, rather than local production. Human CRP significantly increased TF gene expression, protein concentration and activity in VGs. Human CRP also increased PAI-1 concentrations in VGs, although only in vascular endothelial cells. Human CRP stimulated macrophage migration, invasion into VGs, and TF expression. Fibrin deposition was significantly greater in VGs of CRP-Tg mice than in WT controls., Conclusions: CRP accumulates in VGs early after surgery, originating from systemic sources rather than local synthesis. Human CRP promotes TF and PAI-1 expression in VGs, although with different expression patterns. Human CRP stimulates macrophage invasion and fibrin deposition within VGs. These results suggest that CRP induces pathologic changes in VGs that contribute to early VG occlusion., (© 2014 International Society on Thrombosis and Haemostasis.)
- Published
- 2014
- Full Text
- View/download PDF
26. Acute isolated right ventricular myocardial infarction masquerading as acute anterior myocardial infarction.
- Author
-
Sidhu MS, Aggarwal K, and Fay WP
- Subjects
- Adult, Anterior Wall Myocardial Infarction diagnosis, Chest Pain etiology, Diagnosis, Differential, Heart Ventricles, Humans, Male, Myocardial Infarction diagnosis
- Published
- 2014
- Full Text
- View/download PDF
27. Almost everyone over 50 should be put on a statin to reduce the risk of cardiovascular disease: A contrarian view.
- Author
-
Mittal M and Fay WP
- Subjects
- Humans, Middle Aged, Patient Selection, Cardiovascular Diseases prevention & control, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Primary Prevention, Risk Assessment
- Abstract
3-Hydroxy-3-methyl-glutarylCoA reductase inhibitors, or statins, are a mainstay in the treatment of patients with established coronary artery disease (CAD) because of their proven efficacy in reducing cardiovascular death, myocardial infarction, and coronary revascularization procedures in this patient population. Statin therapy has also proven successful in the primary prevention of CAD. However, the absolute reduction in cardiovascular events is lower in primary prevention than in secondary prevention trials, and many of the primary prevention trials enrolled a significant number of patients with established cardiovascular disease and/or other high-risk features, such as diabetes mellitus. For these reasons we do not recommend widespread treatment of the general adult population with a statin. Rather, we advocate a strategy which involves collection of standard clinical data and the use of validated risk-prediction tools to stratify patient risk and limit initiation of a statin to those who are more likely to benefit from such therapy.
- Published
- 2013
28. Homocysteine and thrombosis: guilt by association?
- Author
-
Fay WP
- Subjects
- Animals, Female, Humans, Male, Disease Models, Animal, Hyperhomocysteinemia complications, Hyperhomocysteinemia pathology, Mice, Thrombosis etiology
- Abstract
The long-recognized connection between homocysteine and thrombosis is examined in this issue of Blood in a study conducted by Dayal and colleagues. The results challenge the proposed mechanisms by which disordered homocysteine metabolism triggers vascular disease.
- Published
- 2012
- Full Text
- View/download PDF
29. Antecedent hydrogen sulfide elicits an anti-inflammatory phenotype in postischemic murine small intestine: role of heme oxygenase-1.
- Author
-
Zuidema MY, Peyton KJ, Fay WP, Durante W, and Korthuis RJ
- Subjects
- Analysis of Variance, Animals, Anti-Inflammatory Agents metabolism, Cell Adhesion drug effects, Disease Models, Animal, Dose-Response Relationship, Drug, Endothelial Cells enzymology, Endothelial Cells immunology, Enzyme Inhibitors pharmacology, Heme Oxygenase-1 antagonists & inhibitors, Heme Oxygenase-1 deficiency, Heme Oxygenase-1 genetics, Leukocyte Rolling drug effects, Male, Membrane Proteins antagonists & inhibitors, Membrane Proteins deficiency, Membrane Proteins genetics, Metalloporphyrins pharmacology, Mice, Mice, Inbred C57BL, Mice, Knockout, Microscopy, Fluorescence, Phenotype, Protoporphyrins pharmacology, Reperfusion Injury enzymology, Reperfusion Injury genetics, Reperfusion Injury immunology, Sulfides metabolism, Time Factors, Venules drug effects, Venules enzymology, Venules immunology, Anti-Inflammatory Agents pharmacology, Endothelial Cells drug effects, Heme Oxygenase-1 metabolism, Hydrogen Sulfide metabolism, Intestine, Small blood supply, Membrane Proteins metabolism, Reperfusion Injury prevention & control, Sulfides pharmacology
- Abstract
We recently demonstrated that preconditioning with an exogenous hydrogen sulfide donor (NaHS-PC) 24 h before ischemia and reperfusion (I/R) causes postcapillary venules to shift to an anti-inflammatory phenotype in C57BL/6J wild-type (WT) mice such that these vessels fail to support increases in postischemic leukocyte rolling (LR) and leukocyte adhesion (LA). The objective of the present study was to determine whether heme oxygenase-1 (HO-1) is a mediator of these anti-inflammatory effects noted during I/R in mice preconditioned with NaHS. Intravital fluorescence microscopy was used to visualize LR and LA in single postcapillary venules of the murine small intestine. I/R induced marked increases in LR and LA, effects that were prevented by NaHS-PC. Treatment with the HO inhibitor tin protoporphyrin IX, but not the inactive protoporphyrin CuPPIX, just before reperfusion prevented the anti-inflammatory effects of antecedent NaHS. The anti-inflammatory effects of NaHS-PC were mimicked by preconditioning with hemin, an agent that induces HO-1 expression. We then evaluated the effect of NaHS as a preconditioning stimulus in mice that were genetically deficient in HO-1 (HO-1(-/-) on an H129 background with appropriate WT strain controls). NaHS-PC was ineffective in HO-1(-/-) mice. Our work indicates that HO-1 serves as an effector of the anti-inflammatory effects of NaHS-PC during I/R 24 h later.
- Published
- 2011
- Full Text
- View/download PDF
30. Towards a standardization of the murine ferric chloride-induced carotid arterial thrombosis model.
- Author
-
Owens AP 3rd, Lu Y, Whinna HC, Gachet C, Fay WP, and Mackman N
- Subjects
- Animals, Blood Flow Velocity, Carotid Artery Thrombosis pathology, Carotid Artery Thrombosis physiopathology, Male, Mice, Mice, Inbred C57BL, Models, Cardiovascular, Societies, Medical, Carotid Artery Thrombosis chemically induced, Chlorides toxicity, Disease Models, Animal, Ferric Compounds toxicity
- Published
- 2011
- Full Text
- View/download PDF
31. Multifaceted role of plasminogen activator inhibitor-1 in regulating early remodeling of vein bypass grafts.
- Author
-
Ji Y, Strawn TL, Grunz EA, Stevenson MJ, Lohman AW, Lawrence DA, and Fay WP
- Subjects
- Animals, Cell Movement, Cell Proliferation, Coronary Artery Bypass adverse effects, Fibrin metabolism, Fibrinogen metabolism, Gene Expression, Male, Mice, Mice, Inbred C57BL, Mice, Knockout, Mice, Transgenic, Myocytes, Smooth Muscle pathology, Myocytes, Smooth Muscle physiology, Neointima etiology, Neointima pathology, Neointima physiopathology, Serpin E2 deficiency, Serpin E2 genetics, Tunica Intima pathology, Vena Cava, Inferior pathology, Vitronectin deficiency, Serpin E2 physiology, Vena Cava, Inferior transplantation
- Abstract
Objective: The role of plasminogen activator inhibitor-1 (PAI-1) in vein graft (VG) remodeling is undefined. We examined the effect of PAI-1 on VG intimal hyperplasia and tested the hypothesis that PAI-1 regulates VG thrombin activity., Methods and Results: VGs from wild-type (WT), Pai1(-/-), and PAI-1-transgenic mice were implanted into WT, Pai1(-/-), or PAI-1-transgenic arteries. VG remodeling was assessed 4 weeks later. Intimal hyperplasia was significantly greater in PAI-1-deficient mice than in WT mice. The proliferative effect of PAI-1 deficiency was retained in vitronectin-deficient mice, suggesting that PAI-1's antiproteolytic function plays a key role in regulating intimal hyperplasia. Thrombin-induced proliferation of PAI-1-deficient venous smooth muscle cells (SMC) was significantly greater than that of WT SMC, and thrombin activity was significantly higher in PAI-1-deficient VGs than in WT VGs. Increased PAI-1 expression, which has been associated with obstructive VG disease, did not increase intimal hyperplasia., Conclusions: Decreased PAI-1 expression (1) promotes intimal hyperplasia by pathways that do not require vitronectin and (2) increases thrombin activity in VG. PAI-1 overexpression, although it promotes SMC migration in vitro, did not increase intimal hyperplasia. These results challenge the concept that PAI-1 drives nonthrombotic obstructive disease in VG and suggest that PAI-1's antiproteolytic function, including its antithrombin activity, inhibits intimal hyperplasia.
- Published
- 2011
- Full Text
- View/download PDF
32. Thrombosis, physical activity, and acute coronary syndromes.
- Author
-
Kumar A, Kar S, and Fay WP
- Subjects
- Acute Coronary Syndrome prevention & control, Atherosclerosis epidemiology, Blood Coagulation, Coronary Disease epidemiology, Coronary Thrombosis physiopathology, Coronary Thrombosis prevention & control, Fibrinolysis, Humans, Plaque, Atherosclerotic physiopathology, Platelet Aggregation, Acute Coronary Syndrome physiopathology, Atherosclerosis prevention & control, Coronary Disease prevention & control, Motor Activity physiology
- Abstract
Acute coronary syndromes (ACS) are common, life-threatening cardiac disorders that typically are triggered by rupture or erosion of an atherosclerotic plaque. Platelet deposition and activation of the blood coagulation cascade in response to plaque disruption lead to the formation of a platelet-fibrin thrombus, which can grow rapidly, obstruct coronary blood flow, and cause myocardial ischemia and/or infarction. Several clinical studies have examined the relationship between physical activity and ACS, and numerous preclinical and clinical studies have examined specific effects of sustained physical training and acute physical activity on atherosclerotic plaque rupture, platelet function, and formation and clearance of intravascular fibrin. This article reviews the available literature regarding the role of physical activity in determining the incidence of atherosclerotic plaque rupture and the pace and extent of thrombus formation after plaque rupture.
- Published
- 2011
- Full Text
- View/download PDF
33. Intravital fluorescence microscopy improves thrombosis phenotype scoring in mice.
- Author
-
Fay WP
- Subjects
- Animals, Mice, Phenotype, Microscopy, Fluorescence methods, Thrombosis diagnosis
- Published
- 2011
- Full Text
- View/download PDF
34. Linking inflammation and thrombosis: Role of C-reactive protein.
- Author
-
Fay WP
- Abstract
C-reactive protein (CRP) is a biomarker of inflammation. Increased plasma levels of CRP are associated with an increased risk of myocardial infarction. However, the correlation between plasma CRP concentration and atherosclerotic plaque burden is poor. Based on these observations, it has been hypothesized that CRP increases the risk of myocardial infarction by promoting thrombosis. This article reviews available data that link enhanced CRP expression to increased risk of thrombosis, with a focus on the effects of CRP on hemostasis, platelet function, and fibrinolysis. Overall, the available data support the hypothesis that CRP is an important mechanistic link between inflammation and thrombosis.
- Published
- 2010
- Full Text
- View/download PDF
35. Endothelial-derived tissue factor pathway inhibitor regulates arterial thrombosis but is not required for development or hemostasis.
- Author
-
White TA, Johnson T, Zarzhevsky N, Tom C, Delacroix S, Holroyd EW, Maroney SA, Singh R, Pan S, Fay WP, van Deursen J, Mast AE, Sandhu GS, and Simari RD
- Subjects
- Animals, Arteries metabolism, Arteries pathology, Female, Kaplan-Meier Estimate, Lipoproteins genetics, Lipoproteins metabolism, Male, Mice, Mice, Inbred C57BL, Mice, Knockout, Mice, Transgenic, Monocytes cytology, Monocytes metabolism, Receptor Protein-Tyrosine Kinases genetics, Receptor Protein-Tyrosine Kinases metabolism, Receptor, TIE-2, Thrombosis metabolism, Endothelial Cells metabolism, Hemostasis, Lipoproteins blood, Thrombosis blood
- Abstract
The antithrombotic surface of endothelium is regulated in a coordinated manner. Tissue factor pathway inhibitor (TFPI) localized at the endothelial cell surface regulates the production of FXa by inhibiting the TF/VIIa complex. Systemic homozygotic deletion of the first Kunitz (K1) domain of TFPI results in intrauterine lethality in mice. Here we define the cellular sources of TFPI and their role in development, hemostasis, and thrombosis using TFPI conditional knockout mice. We used a Cre-lox strategy and generated mice with a floxed exon 4 (TFPI(Flox)) which encodes for the TFPI-K1 domain. Mice bred into Tie2-Cre and LysM-Cre lines to delete TFPI-K1 in endothelial (TFPI(Tie2)) and myelomonocytic (TFPI(LysM)) cells resulted in viable and fertile offspring. Plasma TFPI activity was reduced in the TFPI(Tie2) (71% ± 0.9%, P < .001) and TFPI(LysM) (19% ± 0.6%, P < .001) compared with TFPI(Flox) littermate controls. Tail and cuticle bleeding were unaffected. However, TFPI(Tie2) mice but not TFPI(LysM) mice had increased ferric chloride-induced arterial thrombosis. Taken together, the data reveal distinct roles for endothelial- and myelomonocytic-derived TFPI.
- Published
- 2010
- Full Text
- View/download PDF
36. Plasminogen activator inhibitor-1 and vitronectin expression level and stoichiometry regulate vascular smooth muscle cell migration through physiological collagen matrices.
- Author
-
Garg N, Goyal N, Strawn TL, Wu J, Mann KM, Lawrence DA, and Fay WP
- Subjects
- Animals, Aorta cytology, Cell Movement, Gels chemistry, Humans, Low Density Lipoprotein Receptor-Related Protein-1 metabolism, Mice, Mice, Inbred C57BL, Mice, Transgenic, Plasminogen Activator Inhibitor 1 genetics, Vitronectin genetics, Collagen chemistry, Gene Expression Regulation, Muscle, Smooth cytology, Muscle, Smooth, Vascular cytology, Plasminogen Activator Inhibitor 1 metabolism, Vitronectin metabolism
- Abstract
Background: Vascular smooth muscle cell (VSMC) migration is a critical process in arterial remodeling. Purified plasminogen activator inhibitor-1 (PAI-1) is reported to both promote and inhibit VSMC migration on two-dimensional (D) surfaces., Objective: To determine the effects of PAI-1 and vitronectin (VN) expressed by VSMC themselves on migration through physiological collagen matrices., Methods: We studied migration of wild-type (WT), PAI-1-deficient, VN-deficient, PAI-1/VN doubly-deficient (DKO) and PAI-1-transgenic (Tg) VSMC through three-D collagen gels., Results: WT VSMC migrated significantly slower than PAI-1- and VN-deficient VSMC, but significantly faster than DKO VSMC. Experiments with recombinant PAI-1 suggested that basal VSMC PAI-1 expression inhibits migration by binding VN, which is secreted by VSMC and binds collagen. However, PAI-1-over-expressing Tg VSMC migrated faster than WT VSMC. Reconstitution experiments with recombinant PAI-1 mutants suggested that the pro-migratory effect of PAI-1 over-expression required its anti-plasminogen activator (PA) and LDL receptor-related protein (LRP) binding functions, but not VN binding. While promoting VSMC migration in the absence of PAI-1, VN inhibited the pro-migratory effect of active PAI-1., Conclusions: In isolation, VN and PAI-1 are each pro-migratory. However, via formation of a high-affinity, non-motogenic complex, PAI-1 and VN each buffers the other's pro-migratory effect. The level of PAI-1 expression by VSMC and the concentration of VN in extracellular matrix are critical determinants of whether PAI-1 and VN promote or inhibit migration. These findings help to rectify previously conflicting reports and suggest that PAI-1/VN stoichiometry plays an important role in VSMC migration and vascular remodeling., (© 2010 International Society on Thrombosis and Haemostasis.)
- Published
- 2010
- Full Text
- View/download PDF
37. Recombinant plasminogen activator inhibitor-1 inhibits intimal hyperplasia.
- Author
-
Wu J, Peng L, McMahon GA, Lawrence DA, and Fay WP
- Subjects
- Animals, Apoptosis drug effects, Carotid Arteries drug effects, Carotid Arteries pathology, Cell Movement, Cell Proliferation drug effects, Cells, Cultured, Hyperplasia, Low Density Lipoprotein Receptor-Related Protein-1 physiology, Male, Mice, Mice, Inbred C57BL, Muscle, Smooth, Vascular cytology, Muscle, Smooth, Vascular drug effects, Myocytes, Smooth Muscle physiology, Rats, Rats, Sprague-Dawley, Recombinant Proteins pharmacology, Tunica Intima pathology, Plasminogen Activator Inhibitor 1 pharmacology, Tunica Intima drug effects, Vitronectin physiology
- Abstract
Objective: Plasminogen activator inhibitor-1 (PAI-1) overexpression is implicated in vascular disease. However, the effects of a primary increase in PAI-1 expression on arterial remodeling are poorly defined. We tested the hypothesis that recombinant PAI-1 inhibits intimal hyperplasia after vascular injury., Methods and Results: Rats underwent carotid artery injury and received intraperitoneal injections of saline or mutant forms of PAI-1 for 14 days, including an active stable mutant (PAI-1-14-1b), a mutant lacking anti-PA activity (PAI-1-R), or a mutant defective in vitronectin (VN) binding (PAI-1-K). All forms of PAI-1 significantly inhibited neointima formation, whereas elastase-cleaved PAI-1, which lacks both anti-PA and VN-binding functions, did not. Similar effects were observed in a murine model. However, the antiproliferative effect of PAI-1-R was lost in Vn(-/-) mice, suggesting that PAI-1 can inhibit intimal hyperplasia in vivo by a VN-dependent pathway not involving direct inhibition of proteases. In vitro, recombinant PAI-1 inhibited wild-type vascular smooth muscle cell (VSMC) proliferation, promoted apoptosis, and inhibited migration. These effects were lost in VN-deficient VSMCs., Conclusions: Recombinant PAI-1 inhibits intimal hyperplasia by inhibiting proteases and binding VN. VN is a key determinant of the antiproliferative effect of PAI-1 overexpression. PAI-1-R has therapeutic potential to inhibit vascular restenosis without promoting thrombosis.
- Published
- 2009
- Full Text
- View/download PDF
38. Impact of preemptive warfarin dose reduction on anticoagulation after initiation of trimethoprim-sulfamethoxazole or levofloxacin.
- Author
-
Ahmed A, Stephens JC, Kaus CA, and Fay WP
- Subjects
- Aged, Aged, 80 and over, Drug Administration Schedule, Drug Interactions, Drug Monitoring, Female, Humans, International Normalized Ratio, Male, Middle Aged, Anti-Infective Agents administration & dosage, Anticoagulants administration & dosage, Blood Coagulation drug effects, Levofloxacin, Ofloxacin administration & dosage, Trimethoprim, Sulfamethoxazole Drug Combination administration & dosage, Warfarin administration & dosage
- Abstract
Background: Antibiotics can potentiate warfarin anticoagulation. While preemptive warfarin dose reduction (DR) upon initiation of antibiotics has been advocated by experts, there are no published data regarding the efficacy of this strategy vs. the conventional strategy of not changing warfarin dose and carefully following international normalized ratio (INR) results., Methods and Results: We compared the efficacy of preemptive 10-20% DR vs. no change in warfarin dosing in 40 chronically anticoagulated patients initiating trimethoprim-sulfamethoxazole (TMP-SMX) or levofloxacin. Eighteen patients received preemptive warfarin DR and 22 control patients underwent no change in warfarin dosing. There was no difference between the DR and control groups in the mean INR before beginning antibiotic therapy (2.53 +/- 0.12 vs. 2.52 +/- 0.11; P > 0.9). Mean interval between initiation of antibiotic and next INR was 5.1 +/- 0.4 vs. 4.7 +/- 0.5 days for DR vs. control patients, respectively (P > 0.5). For both TMP-SMX and levofloxacin, patients managed with a preemptive warfarin DR strategy did not exhibit a statistically significant change in the INR after initiating antibiotic therapy. In contrast, for each antibiotic, control group patients exhibited a significant increase in mean post-antibiotic INR compared to mean pre-antibiotic INR, though the effect was more pronounced in patients treated with TMP-SMX than with levofloxacin. Of DR group patients who were treated with TMP-SMX, none (0/8) developed a subtherapeutic INR, while 40% (4/10) of levofloxacin-treated patients developed a sub-therapeutic INR. Supra-therapeutic INR results led to transient interruption of warfarin dosing in 2 patients (11%) in the DR group vs. 12 patients (55%) in the control group (P = 0.007)., Conclusions: Prophylactic warfarin DR of 10-20% is effective in maintaining therapeutic anticoagulation in patients initiating TMP-SMX. An expectant strategy consisting of no change in warfarin dosing with short-term INR follow-up appears reasonable in patients treated with levofloxacin.
- Published
- 2008
- Full Text
- View/download PDF
39. C-reactive protein enhances tissue factor expression by vascular smooth muscle cells: mechanisms and in vivo significance.
- Author
-
Wu J, Stevenson MJ, Brown JM, Grunz EA, Strawn TL, and Fay WP
- Subjects
- Animals, Base Sequence, C-Reactive Protein genetics, Cardiovascular Diseases etiology, Cardiovascular Diseases metabolism, Carotid Arteries cytology, Carotid Arteries metabolism, DNA Primers genetics, Humans, Lipoproteins metabolism, MAP Kinase Signaling System, Male, Mice, Mice, Congenic, Mice, Inbred C57BL, Mice, Transgenic, Muscle, Smooth, Vascular cytology, Myocytes, Smooth Muscle metabolism, Oxidative Stress, RNA, Small Interfering genetics, Receptors, IgG antagonists & inhibitors, Receptors, IgG genetics, Receptors, IgG metabolism, Thromboplastin genetics, Up-Regulation, C-Reactive Protein metabolism, Muscle, Smooth, Vascular metabolism, Thromboplastin metabolism
- Abstract
Objective: We examined the impact of C-reactive protein (CRP) on vascular smooth muscle cell (VSMC) expression of tissue factor (TF) and TF pathway inhibitor (TFPI)., Methods and Results: TF mRNA, protein, and activity levels were significantly higher in VSMCs isolated from CRP-transgenic (Tg) mice than from wild-type (WT) mice. TFPI expression was significantly downregulated in CRP-Tg versus WT VSMCs. Transfection of human VSMCs with CRP expression plasmid significantly increased TF expression and decreased TFPI expression. Gene silencing of Fc gamma receptor IIIa (Fc gammaRIIIa) blocked the effect of CRP on VSMC TF expression. CRP activated p44/42, but not p38 or JNK MAP kinase (MAPK), and the effect of CRP on TF expression was blocked by pharmacological inhibitor of p44/42, but not p38 or JNK MAPK. Reactive oxygen species (ROS) scavengers blocked CRP-induced upregulation of VSMC TF expression. In vivo analyses revealed significant increases in TF expression and decreases in TFPI expression in carotid arteries of CRP-Tg mice versus WT mice., Conclusions: CRP increases TF and decreases TFPI expression by VSMCs in vitro and in vivo. Induction of TF expression by CRP is mediated by Fc gammaRIIIa, p44/42 MAPK, and ROS generation. These data offer important insights into the role of CRP in the pathogenesis of arterial thrombosis.
- Published
- 2008
- Full Text
- View/download PDF
40. Double knockouts reveal that protein tyrosine phosphatase 1B is a physiological target of calpain-1 in platelets.
- Author
-
Kuchay SM, Kim N, Grunz EA, Fay WP, and Chishti AH
- Subjects
- Animals, Blood Coagulation, Calpain genetics, Mice, Mice, Knockout, Platelet Aggregation physiology, Protein Tyrosine Phosphatase, Non-Receptor Type 1 antagonists & inhibitors, Protein Tyrosine Phosphatase, Non-Receptor Type 1 genetics, Signal Transduction physiology, Thrombosis metabolism, Vanadates metabolism, Blood Platelets metabolism, Calpain metabolism, Protein Tyrosine Phosphatase, Non-Receptor Type 1 metabolism
- Abstract
Calpains are ubiquitous calcium-regulated cysteine proteases that have been implicated in cytoskeletal organization, cell proliferation, apoptosis, cell motility, and hemostasis. Gene targeting was used to evaluate the physiological function of mouse calpain-1 and establish that its inactivation results in reduced platelet aggregation and clot retraction potentially by causing dephosphorylation of platelet proteins. Here, we report that calpain-1 null (Capn1-/-) platelets accumulate protein tyrosine phosphatase 1B (PTP1B), which correlates with enhanced tyrosine phosphatase activity and dephosphorylation of multiple substrates. Treatment of Capn1-/- platelets with bis(N,N-dimethylhydroxamido)hydroxooxovanadate, an inhibitor of tyrosine phosphatases, corrected the aggregation defect and recovered impaired clot retraction. More importantly, platelet aggregation, clot retraction, and tyrosine dephosphorylation defects were rescued in the double knockout mice lacking both calpain-1 and PTP1B. Further evaluation of mutant mice by the ferric chloride-induced arterial injury model suggests that the Capn1-/- mice are relatively resistant to thrombosis in vivo. Together, our results demonstrate that PTP1B is a physiological target of calpain-1 and suggest that a similar mechanism may regulate calpain-1-mediated tyrosine dephosphorylation in other cells.
- Published
- 2007
- Full Text
- View/download PDF
41. Plasminogen activator inhibitor-1 and restenosis.
- Author
-
Garg N and Fay WP
- Subjects
- Animals, Coronary Restenosis etiology, Coronary Restenosis prevention & control, Humans, Hyperplasia etiology, Hyperplasia metabolism, Tunica Intima pathology, Angioplasty, Balloon, Coronary, Coronary Restenosis blood, Plasminogen Activator Inhibitor 1 metabolism
- Abstract
Despite the introduction of drug-eluting stents restenosis remains an important clinical problem. In this review we examine the role of plasminogen activator inhibitor-1 (PAI-1) in controlling restenosis after balloon angioplasty and stent implantation.
- Published
- 2007
- Full Text
- View/download PDF
42. A comparison of anticoagulation results of patients managed with narrow vs. standard international normalized ratio target ranges.
- Author
-
Meier DJ, Seva S, and Fay WP
- Subjects
- Adult, Aged, Anticoagulants adverse effects, Blood Coagulation drug effects, Female, Hemorrhage prevention & control, Humans, Male, Middle Aged, Retrospective Studies, Thrombosis prevention & control, Warfarin adverse effects, Anticoagulants therapeutic use, International Normalized Ratio, Warfarin therapeutic use
- Published
- 2007
- Full Text
- View/download PDF
43. Vascular functions of the plasminogen activation system.
- Author
-
Fay WP, Garg N, and Sunkar M
- Subjects
- Animals, Atherosclerosis blood, Atherosclerosis pathology, Disease Models, Animal, Endothelium, Vascular injuries, Endothelium, Vascular pathology, Humans, Hyperplasia, Mice, Mice, Knockout, Plasminogen genetics, Plasminogen Activator Inhibitor 1 genetics, Plasminogen Activators metabolism, Research Design, Species Specificity, Thrombosis blood, Atherosclerosis metabolism, Endothelium, Vascular metabolism, Fibrinolysis, Plasminogen metabolism, Plasminogen Activator Inhibitor 1 metabolism, Thrombosis metabolism
- Abstract
The plasminogen activator (PA) system, which controls the formation and activity of plasmin, plays a key role in modulating hemostasis, thrombosis, and several other biological processes. While a great deal is known about the function of the PA system, it remains a focus of intensive investigation, and the list of biological pathways and human diseases that are modulated by normal and pathologic function of its components continues to lengthen. Because of remarkable advances in molecular genetics, the laboratory mouse has become the most useful animal system to study the normal and pathologic functions of the PA system. The purpose of this review is to summarize studies that have used genetically modified mice to examine the functions of the PA system in hemostasis and thrombosis, intimal hyperplasia after vascular injury, and atherosclerosis. Particular emphasis is placed on the vascular functions of PA inhibitor-1, a key regulator of the PA system, and the multiple variables that appear to account for the complex role of PA inhibitor-1 in regulating vascular remodeling. Lastly, the strengths and limitations of using mice to model human vascular disease processes are discussed.
- Published
- 2007
- Full Text
- View/download PDF
44. The duration of anticoagulation bridging therapy in clinical practice may significantly exceed that observed in clinical trials.
- Author
-
Deerhake JP, Merz JC, Cooper JV, Eagle KA, and Fay WP
- Subjects
- Adult, Aged, Ambulatory Care, Atrial Fibrillation, Clinical Trials as Topic, Drug Administration Schedule, Drug Interactions, Evidence-Based Medicine, Female, Humans, Male, Middle Aged, Retrospective Studies, Thrombosis drug therapy, Anticoagulants administration & dosage, Drug Monitoring, Heparin, Low-Molecular-Weight administration & dosage, International Normalized Ratio, Practice Patterns, Physicians' statistics & numerical data, Warfarin therapeutic use
- Abstract
Background: Clinical trials involving frequent, standardized monitoring of the international normalized ratio (INR) demonstrated that a short course of low-molecular-weight-heparin (LMWH) can successfully bridge patients to oral anticoagulation. However, rigidly performed INR testing is often not feasible in the outpatient setting in actual clinical practice. The purpose of this study was to determine if the anticoagulation results of clinical trials of LMWH bridging therapy are also achieved in a single-center clinical practice setting., Methods: We conducted a retrospective analysis of 100 patients initiating warfarin while receiving LMWH under the care of a university-based anticoagulation management service., Results: Mean patient age was 56.1 +/- 16.3 years. The commonest indications for anticoagulation were venous thrombosis (57%) and atrial fibrillation (25%). Mean initial warfarin dose was 5.1 +/- 1.8 mg/day; 30% of patients received antiplatelet therapy. The mean total duration of LMWH therapy was 12.0 +/- 8.2 days, of which 9.8 +/- 8.0 days (median 7.5 days; interquartile range 4.3-13.0 days) occurred in the outpatient setting. Forty-one percent of patients received outpatient LMWH for < 7 days, 40% for 7-14 days, and 19% for > 14 days. A mean of 3.9 +/- 2.0 INRs were performed during LMWH therapy. Complications included 11 minor and 1 major bleeding episodes and 1 thrombotic event., Conclusions: The duration of LMWH bridging therapy in practice may be significantly greater than previously reported in clinical trials, and the incidence of patients requiring prolonged (>14 days) LMWH therapy is relatively high. Outpatient LMWH as employed in clinical practice safely bridges patients to oral anticoagulation. Strategies to shorten the duration of LMWH therapy are needed and are likely to improve clinical outcomes and reduce health care expenses. In prospective clinical trials low-molecular-weight-heparin (LMWH) has proven effective in transitioning patients with venous thromboembolic disease to therapeutic warfarin anticoagulation. However, it is unknown if the anticoagulation results obtained in these trials, which involved rigidly performed anticoagulation monitoring, are achieved in standard clinical practice involving patients with a variety of indications for anticoagulation. We conducted a retrospective analysis of 100 patients initiating warfarin while receiving LMWH under the management of a university-based anticoagulation management service. The mean total duration of LMWH therapy was 12.0 +/- 8.2 days, of which 9.8 +/- 8.0 days (median 7.5 days; interquartile range 4.3-13.0 days) occurred in the outpatient setting. Forty-one percent of patients received outpatient LMWH for <7 days, 40% for 7-14 days, and 19% for >14 days. We conclude that the duration of LMWH bridging therapy in practice may be significantly greater than previously reported in clinical trials, and the incidence of patients requiring prolonged (>14 days) LMWH therapy is relatively high.
- Published
- 2007
- Full Text
- View/download PDF
45. Atherosclerosis in mice is not affected by a reduction in tissue factor expression.
- Author
-
Tilley RE, Pedersen B, Pawlinski R, Sato Y, Erlich JH, Shen Y, Day S, Huang Y, Eitzman DT, Boisvert WA, Curtiss LK, Fay WP, and Mackman N
- Subjects
- Animals, Aorta pathology, Aorta physiology, Apolipoproteins E genetics, Atherosclerosis pathology, Bone Marrow Transplantation, Gene Expression, Hematopoietic Stem Cells metabolism, Mice, Mice, Inbred C57BL, Mice, Mutant Strains, Receptors, LDL genetics, Atherosclerosis metabolism, Atherosclerosis physiopathology, Thromboplastin genetics, Thromboplastin metabolism
- Abstract
Objective: To determine whether tissue factor (TF) contributes to the progression of atherosclerotic lesions in mice., Methods and Results: We determined the effect of a 50% reduction of TF levels in all cells on atherosclerosis in apolipoprotein E-deficient (apoE(-/-)) mice. No differences were observed in the extent of atherosclerosis in apoE(-/-)/TF(+/+) and apoE(-/-)/TF(+/-) mice fed regular chow for 34 weeks. Atherosclerosis could not be analyzed in apoE(-/-) mice expressing low levels of TF because of premature death of these mice. Macrophages are a major source of TF in atherosclerotic plaques. Therefore, in a second series of experiments, we investigated the effect on atherosclerosis of selectively reducing hematopoietic cell-derived TF by transplanting bone marrow from mice expressing low levels of TF into low-density lipoprotein receptor deficient (LDLR(-/-)) mice. Atherosclerosis within the arterial tree and aortic root were similar in LDLR(-/-) mice with low-TF bone marrow compared with control bone marrow (TF(+/+) or TF(+/-)) after 4 and 16 weeks on an atherogenic diet. Furthermore, the cellular composition of the aortic root lesions was similar between the 2 groups., Conclusions: Our data indicate that either a 50% reduction of TF in all cells or a selective reduction in hematopoietic cell-derived TF does not affect the development of atherosclerotic lesions in mice.
- Published
- 2006
- Full Text
- View/download PDF
46. MT1-matrix metalloproteinase directs arterial wall invasion and neointima formation by vascular smooth muscle cells.
- Author
-
Filippov S, Koenig GC, Chun TH, Hotary KB, Ota I, Bugge TH, Roberts JD, Fay WP, Birkedal-Hansen H, Holmbeck K, Sabeh F, Allen ED, and Weiss SJ
- Subjects
- Animals, Apoptosis physiology, Arteries ultrastructure, Cloning, Molecular, Fluorescent Antibody Technique, Gene Transfer Techniques, In Situ Nick-End Labeling, Male, Matrix Metalloproteinase 14, Matrix Metalloproteinases genetics, Matrix Metalloproteinases, Membrane-Associated, Mice, Mice, Mutant Strains, Microscopy, Electron, Myocytes, Smooth Muscle ultrastructure, Reverse Transcriptase Polymerase Chain Reaction, Arteries metabolism, Cell Movement physiology, Collagen metabolism, Extracellular Matrix metabolism, Matrix Metalloproteinases metabolism, Myocytes, Smooth Muscle metabolism, Vascular Diseases metabolism
- Abstract
During pathologic vessel remodeling, vascular smooth muscle cells (VSMCs) embedded within the collagen-rich matrix of the artery wall mobilize uncharacterized proteolytic systems to infiltrate the subendothelial space and generate neointimal lesions. Although the VSMC-derived serine proteinases, plasminogen activator and plasminogen, the cysteine proteinases, cathepsins L, S, and K, and the matrix metalloproteinases MMP-2 and MMP-9 have each been linked to pathologic matrix-remodeling states in vitro and in vivo, the role that these or other proteinases play in allowing VSMCs to negotiate the three-dimensional (3-D) cross-linked extracellular matrix of the arterial wall remains undefined. Herein, we demonstrate that VSMCs proteolytically remodel and invade collagenous barriers independently of plasmin, cathepsins L, S, or K, MMP-2, or MMP-9. Instead, we identify the membrane-anchored matrix metalloproteinase, MT1-MMP, as the key pericellular collagenolysin that controls the ability of VSMCs to degrade and infiltrate 3-D barriers of interstitial collagen, including the arterial wall. Furthermore, genetic deletion of the proteinase affords mice with a protected status against neointimal hyperplasia and lumen narrowing in vivo. These studies suggest that therapeutic interventions designed to target MT1-MMP could prove beneficial in a range of human vascular disease states associated with the destructive remodeling of the vessel wall extracellular matrix.
- Published
- 2005
- Full Text
- View/download PDF
47. Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall.
- Author
-
Day SM, Reeve JL, Pedersen B, Farris DM, Myers DD, Im M, Wakefield TW, Mackman N, and Fay WP
- Subjects
- Animals, Blood Cell Count, Bone Marrow metabolism, Bone Marrow Transplantation, Erythrocyte Membrane metabolism, Factor Xa metabolism, Gene Deletion, Leukocytes cytology, Leukocytes metabolism, Mice, Mice, Knockout, Thromboplastin deficiency, Thromboplastin genetics, Thrombosis genetics, Blood Vessels cytology, Blood Vessels metabolism, Thromboplastin metabolism, Thrombosis metabolism, Thrombosis pathology
- Abstract
Leukocytes and leukocyte-derived microparticles contain low levels of tissue factor (TF) and incorporate into forming thrombi. Although this circulating pool of TF has been proposed to play a key role in thrombosis, its functional significance relative to that of vascular wall TF is poorly defined. We tested the hypothesis that leukocyte-derived TF contributes to thrombus formation in vivo. Compared to wild-type mice, mice with severe TF deficiency (ie, TF(-/-), hTF-Tg+, or "low-TF") demonstrated markedly impaired thrombus formation after carotid artery injury or inferior vena cava ligation. A bone marrow transplantation strategy was used to modulate levels of leukocyte-derived TF. Transplantation of low-TF marrow into wild-type mice did not suppress arterial or venous thrombus formation. Similarly, transplantation of wild-type marrow into low-TF mice did not accelerate thrombosis. In vitro analyses revealed that TF activity in the blood was very low and was markedly exceeded by that present in the vessel wall. Therefore, our results suggest that thrombus formation in the arterial and venous macrovasculature is driven primarily by TF derived from the blood vessel wall as opposed to leukocytes.
- Published
- 2005
- Full Text
- View/download PDF
48. Factor VLeiden inhibits fibrinolysis in vivo.
- Author
-
Parker AC, Mundada LV, Schmaier AH, and Fay WP
- Subjects
- Animals, Carboxypeptidase B2 antagonists & inhibitors, In Vitro Techniques, Mice, Mice, Inbred C57BL, Mice, Mutant Strains, Mutation, Pulmonary Embolism blood, Thrombosis blood, Factor V genetics, Fibrinolysis physiology
- Abstract
Background: Factor V(Leiden) (fV(Leiden)) predisposes to thrombosis by enhancing thrombin formation. This study tested the hypothesis that fV(Leiden) inhibits fibrinolysis in vivo., Methods and Results: Radiolabeled clots were injected into the jugular veins of wild-type mice and mice heterozygous (fV(+/Q)) or homozygous (fV(Q/Q)) for fV(Leiden). Mean percent clot lysis 5 hours later was significantly reduced in fV(Q/Q) mice (14.3+/-3.6%, n=13) compared with wild-type mice (40.2+/-7.0%, n=17; P<0.01) and intermediate in fV(+/Q) mice (29.4+/-8.7%, n=9; P<0.03 versus fV(Q/Q), P=0.36 versus wild type). The rate of in vitro lysis of plasma clots prepared from fV(+/Q) or fV(Q/Q) mice was significantly slower than that of wild-type plasma clots, whereas in vitro clot lysis did not differ significantly between groups after inhibiting thrombin-activatable fibrinolysis inhibitor., Conclusions: fV(Leiden) inhibits fibrinolysis in vivo, suggesting an additional pathway by which this mutation promotes thrombosis.
- Published
- 2004
- Full Text
- View/download PDF
49. Antidote-mediated control of an anticoagulant aptamer in vivo.
- Author
-
Rusconi CP, Roberts JD, Pitoc GA, Nimjee SM, White RR, Quick G Jr, Scardino E, Fay WP, and Sullenger BA
- Subjects
- Animals, Blood Coagulation Tests, Carotid Artery Thrombosis drug therapy, Drug Interactions, Drug Therapy, Combination, Mice, Swine, Treatment Outcome, Anticoagulants administration & dosage, Anticoagulants adverse effects, Antidotes administration & dosage, Blood Coagulation drug effects, Hemorrhage chemically induced, Hemorrhage prevention & control, Oligonucleotides administration & dosage, Oligonucleotides adverse effects
- Abstract
Patient safety and treatment outcome could be improved if physicians could rapidly control the activity of therapeutic agents in their patients. Antidote control is the safest way to regulate drug activity, because unlike rapidly clearing drugs, control of the drug activity is independent of underlying patient physiology and co-morbidities. Until recently, however, there was no general method to discover antidote-controlled drugs. Here we demonstrate that the activity and side effects of a specific class of drugs, called aptamers, can be controlled by matched antidotes in vivo. The drug, an anticoagulant aptamer, systemically induces anticoagulation in pigs and inhibits thrombosis in murine models. The antidote rapidly reverses anticoagulation engendered by the drug, and prevents drug-induced bleeding in surgically challenged animals. These results demonstrate that rationally designed drug-antidote pairs can be generated to provide control over drug activities in animals.
- Published
- 2004
- Full Text
- View/download PDF
50. Murine thrombosis models.
- Author
-
Day SM, Reeve JL, Myers DD, and Fay WP
- Subjects
- Anesthesia, Animals, Blood Specimen Collection, Blood Vessels injuries, Methods, Mice, Disease Models, Animal, Thrombosis etiology, Thrombosis pathology, Thrombosis therapy
- Abstract
Due to exciting advances in molecular biology, the laboratory mouse has become an important and frequently used model for studying thrombosis. This article reviews several experimental approaches that have been used to study arterial, venous, and microvascular thrombosis in mice. The advantages and limitations of different models are examined. Related topics of mouse anesthesia, phlebotomy, and in vitro hemostasis testing are also reviewed.
- Published
- 2004
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.